Intravitreal Bevacizumab for the Treatment of Choroidal Neovascularization in Vogt-Koyanagi-Harada Disease - A Prospective Study
Latest Information Update: 06 Jan 2022
At a glance
- Drugs Bevacizumab (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
Most Recent Events
- 04 Jan 2022 Status changed from active, no longer recruiting to completed.
- 13 Jan 2014 New trial record